{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:20:57Z","timestamp":1763018457119,"version":"build-2065373602"},"reference-count":92,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Life-threatening ventricular arrhythmias, such as ventricular tachycardia and ventricular fibrillation remain an ongoing clinical problem and their prevention and treatment require optimization. Conventional antiarrhythmic drugs are associated with significant proarrhythmic effects that often outweigh their benefits. Another option, the implantable cardioverter defibrillator, though clearly the primary therapy for patients at high risk of ventricular arrhythmias, is costly, invasive, and requires regular monitoring. Thus there is a clear need for new antiarrhythmic treatment strategies. Ivabradine, a heartrate-reducing agent, an inhibitor of HCN channels, may be one of such options. In this review we discuss emerging data from experimental studies that indicate new mechanism of action of this drug and further areas of investigation and potential use of ivabradine as an antiarrhythmic agent. However, clinical evidence is limited, and the jury is still out on effects of ivabradine on cardiac ventricular arrhythmias in the clinical setting.<\/jats:p>","DOI":"10.3390\/jcm10204732","type":"journal-article","created":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T13:35:47Z","timestamp":1634304947000},"page":"4732","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effect of Ivabradine on Cardiac Ventricular Arrhythmias: Friend or Foe?"],"prefix":"10.3390","volume":"10","author":[{"given":"Marta","family":"Okni\u0144ska","sequence":"first","affiliation":[{"name":"Centre of Postgraduate Medical Education, Department of Clinical Physiology, ul. Marymoncka 99\/103, 01-813 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6131-6004","authenticated-orcid":false,"given":"Aleksandra","family":"Paterek","sequence":"additional","affiliation":[{"name":"Centre of Postgraduate Medical Education, Department of Clinical Physiology, ul. Marymoncka 99\/103, 01-813 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzanna","family":"Zambrowska","sequence":"additional","affiliation":[{"name":"Centre of Postgraduate Medical Education, Department of Clinical Physiology, ul. Marymoncka 99\/103, 01-813 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urszula","family":"Mackiewicz","sequence":"additional","affiliation":[{"name":"Centre of Postgraduate Medical Education, Department of Clinical Physiology, ul. Marymoncka 99\/103, 01-813 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"M\u0105czewski","sequence":"additional","affiliation":[{"name":"Centre of Postgraduate Medical Education, Department of Clinical Physiology, ul. Marymoncka 99\/103, 01-813 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)","volume":"41","author":"Knuuti","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureThe Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.cardfail.2017.04.014","article-title":"2017 ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure","volume":"23","author":"Yancy","year":"2017","journal-title":"J. Card. Fail."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00003495-200767002-00003","article-title":"The Funny Current","volume":"67","author":"Borer","year":"2007","journal-title":"Drugs"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/351145a0","article-title":"Direct activation of cardiac pacemaker channels by intracellular cyclic AMP","volume":"351","author":"Tortora","year":"1991","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.2174\/1568026616999160315130832","article-title":"HCN Channels Modulators: The Need for Selectivity","volume":"16","author":"Sartiani","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1124\/pr.57.4.13","article-title":"Overview of molecular relationships in the voltage-gated ion channel superfamily","volume":"57","author":"Yu","year":"2005","journal-title":"Pharmacol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev.physiol.63.1.235","article-title":"Molecular diversity of pacemaker ion channels","volume":"63","author":"Kaupp","year":"2001","journal-title":"Annu. Rev. Physiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/35081088","article-title":"Molecular mechanism of cAMP modulation of HCN pacemaker channels","volume":"411","author":"Wainger","year":"2001","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1152\/physrev.00029.2008","article-title":"Hyperpolarization-activated cation channels: From genes to function","volume":"89","author":"Biel","year":"2009","journal-title":"Physiol. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pharmthera.2005.01.005","article-title":"Physiology and pharmacology of the cardiac pacemaker (\u201cfunny\u201d) current","volume":"107","author":"Baruscotti","year":"2005","journal-title":"Pharmacol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3389\/fphys.2019.01599","article-title":"A Brief History of Pacemaking","volume":"10","year":"2020","journal-title":"Front. Physiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1161\/CIRCRESAHA.109.206078","article-title":"A Coupled SYSTEM of Intracellular Ca2+ Clocks and Surface Membrane Voltage Clocks Controls the Timekeeping Mechanism of the Heart\u2019s Pacemaker","volume":"106","author":"Lakatta","year":"2010","journal-title":"Circ. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1161\/01.RES.0000101913.95604.B9","article-title":"Site of Origin and Molecular Substrate of Atrioventricular Junctional Rhythm in the Rabbit Heart","volume":"93","author":"Dobrzynski","year":"2003","journal-title":"Circ. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/CIRCRESAHA.109.208041","article-title":"The role of the funny current in pacemaker activity","volume":"106","year":"2010","journal-title":"Circ. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/cvr\/cvs184","article-title":"Ventricular HCN channels decrease the repolarization reserve in the hypertrophic heart","volume":"95","author":"Hofmann","year":"2012","journal-title":"Cardiovasc. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.coph.2013.12.005","article-title":"HCN channels: New roles in sinoatrial node function","volume":"15","author":"Fenske","year":"2014","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1161\/CIRCEP.115.003070","article-title":"Molecular Mapping of Sinoatrial Node HCN Channel Expression in the Human Heart","volume":"8","author":"Li","year":"2015","journal-title":"Circ. Arrhythmia Electrophysiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00395-009-0031-5","article-title":"Transcription profiling of HCN-channel isotypes throughout mouse cardiac development","volume":"104","author":"Schweizer","year":"2009","journal-title":"Basic Res. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1161\/01.RES.88.5.536","article-title":"I(f) current and spontaneous activity in mouse embryonic ventricular myocytes","volume":"88","author":"Yasui","year":"2001","journal-title":"Circ. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jacc.2014.06.1155","article-title":"The symptom complex of familial sinus node dysfunction and myocardial noncompaction is associated with mutations in the HCN4 channel","volume":"64","author":"Schweizer","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.yjmcc.2008.04.013","article-title":"Molecular basis of funny current (If) in normal and failing human heart","volume":"45","author":"Stillitano","year":"2008","journal-title":"J. Mol. Cell Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1161\/01.CIR.97.1.55","article-title":"Hyperpolarization-Activated Inward Current in Ventricular Myocytes From Normal and Failing Human Hearts","volume":"97","author":"Hoppe","year":"1998","journal-title":"Circulation"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1161\/01.CIR.95.3.568","article-title":"Characterization of the hyperpolarization-activated current, I(f), in ventricular myocytes from human failing heart","volume":"95","author":"Cerbai","year":"1997","journal-title":"Circulation"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/jcp.24507","article-title":"Ivabradine Protects Against Ventricular Arrhythmias in Acute Myocardial Infarction in the Rat","volume":"229","author":"Mackiewicz","year":"2014","journal-title":"J. Cell. Physiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.bbrc.2010.04.003","article-title":"Dynamic changes in HCN2, HCN4, KCNE1, and KCNE2 expression in ventricular cells from acute myocardial infarction rat hearts","volume":"395","author":"Xia","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1111\/j.1476-5381.2011.01627.x","article-title":"Long-term treatment with ivabradine in post-myocardial infarcted rats counteracts f-channel overexpression","volume":"165","author":"Suffredini","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1113\/jphysiol.2003.041954","article-title":"Regional distribution of hyperpolarization-activated current (If) and hyperpolarization-activated cyclic nucleotide-gated channel mRNA expression in ventricular cells from control and hypertrophied rat hearts","volume":"553","author":"Goren","year":"2003","journal-title":"J. Physiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1161\/01.CIR.94.7.1674","article-title":"Occurrence and Properties of the Hyperpolarization-Activated Current If in Ventricular Myocytes From Normotensive and Hypertensive Rats During Aging","volume":"94","author":"Cerbai","year":"1996","journal-title":"Circulation"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e000150","DOI":"10.1161\/JAHA.113.000150","article-title":"Increased Expression of HCN Channels in the Ventricular Myocardium Contributes to Enhanced Arrhythmicity in Mouse Failing Hearts","volume":"2","author":"Kuwabara","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6310","DOI":"10.1093\/emboj\/cdg601","article-title":"NRSF regulates the fetal cardiac gene program and maintains normal cardiac structure and function","volume":"22","author":"Kuwahara","year":"2003","journal-title":"EMBO J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1476-5381.2011.01782.x","article-title":"Novel blockers of hyperpolarization-activated current with isoform selectivity in recombinant cells and native tissue","volume":"166","author":"Melchiorre","year":"2012","journal-title":"Br. J. Pharmacol."},{"doi-asserted-by":"crossref","unstructured":"Hadova, K., Kralova, E., Doka, G., Bies Pivackova, L., Kmecova, Z., Krenek, P., and Klimas, J. (2021). Isolated downregulation of HCN2 in ventricles of rats with streptozotocin-induced diabetic cardiomyopathy. BMC Cardiovasc. Disord., 21.","key":"ref_33","DOI":"10.1186\/s12872-021-01929-3"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.tcm.2012.05.013","article-title":"The role of HCN channels in ventricular repolarization","volume":"21","author":"Fenske","year":"2011","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/j.jacc.2017.08.038","article-title":"The Clinical Use of Ivabradine","volume":"70","author":"Koruth","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41598-018-37116-2","article-title":"Characterization of drug binding within the HCN1 channel pore","volume":"9","author":"Tanguay","year":"2019","journal-title":"Sci. Rep."},{"doi-asserted-by":"crossref","unstructured":"Bucchi, A., Baruscotti, M., Nardini, M., Barbuti, A., Micheloni, S., Bolognesi, M., and DiFrancesco, D. (2013). Identification of the Molecular Site of Ivabradine Binding to HCN4 Channels. PLoS ONE, 8.","key":"ref_37","DOI":"10.1371\/journal.pone.0053132"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1113\/jphysiol.2005.100776","article-title":"Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels","volume":"572","author":"Bucchi","year":"2006","journal-title":"J. Physiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1124\/mol.105.020701","article-title":"Bradycardic and proarrhythmic properties of sinus node inhibitors","volume":"69","author":"Stieber","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/j.1476-5381.1996.tb16728.x","article-title":"Mechanisms of block of a human cloned potassium channel by the enantiomers of a new bradycardic agent: S-16257-2 and S-16260-2","volume":"117","author":"Valenzuela","year":"1996","journal-title":"Br. J. Pharm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"36","DOI":"10.33594\/000000119","article-title":"Pharmacological Profile of the Bradycardic Agent Ivabradine on Human Cardiac Ion Channels","volume":"53","author":"Haechl","year":"2019","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e001813","DOI":"10.1161\/JAHA.115.001813","article-title":"hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine","volume":"4","author":"Melgari","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.yjmcc.2015.05.009","article-title":"Ivabradine prolongs phase 3 of cardiac repolarization and blocks the hERG1 (KCNH2) current over a concentration-range overlapping with that required to block HCN4","volume":"85","author":"Guo","year":"2015","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ejphar.2011.07.025","article-title":"Electrophysiological effects of ivabradine in dog and human cardiac preparations: Potential antiarrhythmic actions","volume":"668","author":"Koncz","year":"2011","journal-title":"Eur. J. Pharm."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.clinthera.2013.10.007","article-title":"Pharmacokinetic and safety profile of ivabradine in healthy Chinese men: A phase I, randomized, open-label, increasing single- and multiple-dose study","volume":"35","author":"Jiang","year":"2013","journal-title":"Clin. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ijcard.2017.02.055","article-title":"Effective suppression of atrial fibrillation by ivabradine: Novel target for an established drug?","volume":"236","author":"Frommeyer","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.pain.2014.05.021","article-title":"Inflammatory and neuropathic pain are rapidly suppressed by peripheral block of hyperpolarisation-activated cyclic nucleotide-gated ion channels","volume":"155","author":"Young","year":"2014","journal-title":"Pain"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature04710","article-title":"hERG potassium channels and cardiac arrhythmia","volume":"440","author":"Sanguinetti","year":"2006","journal-title":"Nature"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1096\/fj.201700255R","article-title":"Hypoxia reduces mature hERG channels through calpain up-regulation","volume":"31","author":"Lamothe","year":"2017","journal-title":"FASEB J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12012-014-9274-y","article-title":"Torsades de Pointes Induced by the Concomitant Use of Ivabradine and Azithromycin: An Unexpected Dangerous Interaction","volume":"15","author":"Cocco","year":"2015","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_51","first-page":"426","article-title":"Slow junctional rhythm, QTc prolongation and transient torsades de-pointes following combined use of Ivabradine, Diltiazem and Ranolazine","volume":"62","author":"Mittal","year":"2014","journal-title":"J. Assoc. Physicians India"},{"key":"ref_52","first-page":"798","article-title":"Premature ventricular complexes as a trigger for ventricular fibrillation","volume":"63","year":"2010","journal-title":"Rev. Espa\u00f1ola Cardiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-physiol-021014-071622","article-title":"Mechanisms of ventricular arrhythmias: From molecular fluctuations to electrical turbulence","volume":"77","author":"Qu","year":"2015","journal-title":"Annu. Rev. Physiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41569-019-0179-0","article-title":"Animal models of arrhythmia: Classic electrophysiology to genetically modified large animals","volume":"16","author":"Clauss","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pbiomolbio.2020.02.008","article-title":"Cardiomyocyte calcium handling in health and disease: Insights from in vitro and in silico studies","volume":"157","author":"Sutanto","year":"2020","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1152\/physrev.1989.69.4.1049","article-title":"Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction","volume":"69","author":"Janse","year":"1989","journal-title":"Physiol. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"15027","DOI":"10.1038\/s41598-020-71706-3","article-title":"Ivabradine is as effective as metoprolol in the prevention of ventricular arrhythmias in acute non-reperfused myocardial infarction in the rat","volume":"10","author":"Marciszek","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/FJC.0b013e3181913df4","article-title":"Ivabradine Induces an Increase in Ventricular Fibrillation Threshold During Acute Myocardial Ischemia: An Experimental Study","volume":"52","author":"Vaillant","year":"2008","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.resuscitation.2011.03.032","article-title":"Heart rate reduction with ivabradine increases ischaemia-induced ventricular fibrillation threshold: Role of myocyte structure and myocardial perfusion","volume":"82","author":"Vaillant","year":"2011","journal-title":"Resuscitation"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.yjmcc.2013.02.001","article-title":"Selective heart rate reduction with ivabradine slows ischaemia-induced electrophysiological changes and reduces ischaemia-reperfusion-induced ventricular arrhythmias","volume":"59","author":"Ng","year":"2013","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_61","first-page":"1","article-title":"Effects of ivabradine on ventricular electrophysiological remodeling after myocardial infarction in rats","volume":"16","author":"Jiang","year":"2020","journal-title":"Arch. Med. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"111250","DOI":"10.1016\/j.biopha.2021.111250","article-title":"Ivabradine prevents deleterious effects of dopamine therapy in heart failure: No role for HCN4 overexpression","volume":"136","author":"Paterek","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"H435","DOI":"10.1152\/ajpheart.00591.2008","article-title":"Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure","volume":"296","author":"Milliez","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.resuscitation.2012.07.041","article-title":"Ivabradine but not propranolol delays the time to onset of ischaemia-induced ventricular fibrillation by preserving myocardial metabolic energy status","volume":"84","author":"Vaillant","year":"2013","journal-title":"Resuscitation"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1038\/s41467-019-11261-2","article-title":"Augmentation of myocardial I(f) dysregulates calcium homeostasis and causes adverse cardiac remodeling","volume":"10","author":"Yampolsky","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/1440-1681.12790","article-title":"Antiarrhythmic properties of ivabradine in an experimental model of Short-QT- Syndrome","volume":"44","author":"Frommeyer","year":"2017","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/bcpt.12829","article-title":"Ivabradine Reduces Digitalis-induced Ventricular Arrhythmias","volume":"121","author":"Frommeyer","year":"2017","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12012-018-9482-y","article-title":"Ivabradine Aggravates the Proarrhythmic Risk in Experimental Models of Long QT Syndrome","volume":"19","author":"Frommeyer","year":"2019","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3389\/fphar.2019.01566","article-title":"The Hyperpolarization-Activated Cyclic-Nucleotide-Gated Channel Blocker Ivabradine Does Not Prevent Arrhythmias in Catecholaminergic Polymorphic Ventricular Tachycardia","volume":"10","author":"Weisbrod","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/eurheartj\/ehp554","article-title":"Chronic heart rate reduction with ivabradine improves systolic function of the reperfused heart through a dual mechanism involving a direct mechanical effect and a long-term increase in FKBP12\/12.6 expression","volume":"31","author":"Couvreur","year":"2010","journal-title":"Eur. Heart J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"H991","DOI":"10.1152\/ajpheart.00789.2015","article-title":"Ivabradine and metoprolol differentially affect cardiac glucose metabolism despite similar heart rate reduction in a mouse model of dyslipidemia","volume":"311","author":"Vaillant","year":"2016","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nature12537","article-title":"Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation","volume":"502","author":"Erickson","year":"2013","journal-title":"Nature"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.yjmcc.2014.12.019","article-title":"Ectopic automaticity induced in ventricular myocytes by transgenic overexpression of HCN2","volume":"80","author":"Oshita","year":"2015","journal-title":"J. Mol. Cell Cardiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s12576-019-00684-7","article-title":"Overexpression of the HCN2 channel increases the arrhythmogenicity induced by hypokalemia","volume":"69","author":"Oshita","year":"2019","journal-title":"J. Physiol. Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.hrthm.2021.03.020","article-title":"Effect of ivabradine on cardiac arrhythmias: Antiarrhythmic or proarrhythmic?","volume":"18","author":"Marciszek","year":"2021","journal-title":"Heart Rhythm"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.amjcard.2010.10.065","article-title":"Safety of Ivabradine in Patients With Coronary Artery Disease and Left Ventricular Systolic Dysfunction (from the BEAUTIFUL Holter Substudy)","volume":"107","author":"Tendera","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure","volume":"371","author":"Fox","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/ejhf.258","article-title":"Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: Insights from the SHIFT Holter substudy","volume":"17","author":"Borer","year":"2015","journal-title":"Eur. J. Heart Fail."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/2048872613489305","article-title":"Safety of intravenous ivabradine in acute ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention: A randomized, placebo-controlled, double-blind, pilot study","volume":"2","author":"Steg","year":"2013","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.cardfail.2009.05.013","article-title":"Comparison of Ivabradine Versus Metoprolol in Early Phases of Reperfused Anterior Myocardial Infarction With Impaired Left Ventricular Function: Preliminary Findings","volume":"15","author":"Fasullo","year":"2009","journal-title":"J. Card. Fail."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.acvd.2013.12.001","article-title":"Effect of ivabradine on left ventricular remodelling after reperfused myocardial infarction: A pilot study","volume":"107","author":"Gerbaud","year":"2014","journal-title":"Arch. Cardiovasc. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"786","DOI":"10.5603\/KP.a2017.0094","article-title":"Effects of ivabradine and beta-blocker therapy on dobutamine-induced ventricular arrhythmias","volume":"75","author":"Mert","year":"2017","journal-title":"Kardiologia Polska"},{"key":"ref_85","first-page":"402","article-title":"Ivabradine, a novel heart rate slower: Is it a sword of double blades in patients with idiopathic dilated cardiomyopathy?","volume":"11","author":"Rayan","year":"2011","journal-title":"Anadolu Kardiyoloji Dergisi"},{"key":"ref_86","first-page":"36","article-title":"Significant suppression of premature ventricular ectopics with ivabradine in dilated cardiomyopathy","volume":"26","author":"Mughal","year":"2019","journal-title":"Br. J. Cardiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1111\/pace.13446","article-title":"Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia","volume":"41","author":"Vaksmann","year":"2018","journal-title":"Pacing Clin. Electrophysiol. PACE"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/pace.13913","article-title":"Ventricular arrhythmia suppression with ivabradine in a patient with catecholaminergic polymorphic ventricular tachycardia refractory to nadolol, flecainide, and sympathectomy","volume":"43","author":"Kohli","year":"2020","journal-title":"Pacing Clin. Electrophysiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00424-020-02384-3","article-title":"Cardiac and neuronal HCN channelopathies","volume":"472","author":"Rivolta","year":"2020","journal-title":"Pflug. Arch. Eur. J. Physiol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.recesp.2019.06.006","article-title":"Ivabradine for chronic heart rate control in persistent atrial fibrillation. Design of the BRAKE-AF project","volume":"73","author":"Fontenla","year":"2020","journal-title":"Rev. Espa\u00f1ola Cardiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s00246-019-02149-5","article-title":"Ivabradine in Post-operative Junctional Ectopic Tachycardia (JET): Breaking New Ground","volume":"40","author":"Krishna","year":"2019","journal-title":"Pediatric Cardiol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/pace.13402","article-title":"Ivabradine is an effective antiarrhythmic therapy for congenital junctional ectopic tachycardia-induced cardiomyopathy during infancy: Case studies","volume":"41","author":"Ergul","year":"2018","journal-title":"Pacing Clin. Electrophysiol. PACE"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/20\/4732\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:15:17Z","timestamp":1760166917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/20\/4732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,15]]},"references-count":92,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["jcm10204732"],"URL":"https:\/\/doi.org\/10.3390\/jcm10204732","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2021,10,15]]}}}